A compounded blend combining ipamorelin (ghrelin receptor agonist) with tesamorelin (GHRH analogue) for synergistic GH secretion with tesamorelin's additional visceral fat-reducing properties.
Peptide Blend
A compounded blend combining ipamorelin (ghrelin receptor agonist) with tesamorelin (GHRH analogue) for synergistic GH secretion with tesamorelin's additional visceral fat-reducing properties.
6 clinics in our directory offer Ipamorelin + Tesamorelin Blend. Use the button below to find one near you.
Peptide Blend
Adamax is a branded compounded peptide blend typically combining CJC-1295 DAC, Ipamorelin, and BPC-157, formulated to simultaneously stimulate growth hormone secretion, promote tissue repair, and support recovery — often available as a single reconstitution vial.
Peptide Blend
CagriSema, a compounded combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide, studied in Phase 3 REDEFINE trials with approximately 22.7% body weight reduction at 68 weeks.
Peptide Blend
A triple-peptide compounded blend combining AOD-9604 (fat-mobilizing GH fragment) with CJC-1295 and ipamorelin for comprehensive GH-axis optimization with targeted lipolysis.
Peptide Blend
The most widely used compounded GH peptide combination, pairing modified GRF 1-29 (CJC-1295 without DAC) with ipamorelin for a clean, pulsatile GH release that mimics natural secretory patterns.
Articles about Ipamorelin + Tesamorelin Blend and related topics
Amazon quietly delisted bacteriostatic water across 2024–2026 — no press release, no customer notice, listings simply vanished. Behind the removal: a prescription-only label Amazon's policy couldn't accommodate, FDA warning letters turning BAC water into legal evidence of intended human injection use, independent testing that found 9 of 11 Amazon products failed basic quality standards, and a growing wave of sterile water lawsuits that made the liability math untenable. Here is a complete breakdown of what happened and where to get pharmaceutical-grade BAC water now.
The FDA's Pharmacy Compounding Advisory Committee voted 8–6 to recommend six popular peptides — including BPC-157 and TB-500 — for the 503A Bulk Drug Substances list. The vote is historic but non-binding: formal FDA rulemaking, which typically takes 8–12 months, must follow before compounding pharmacies have legal authority to prepare them. Here is a complete breakdown of the vote, what it means for access, and what happens next.
How-To GuidesA detailed, clinician-informed guide to BPC-157 reconstitution — covering diluent selection, step-by-step mixing instructions, concentration math with worked examples, storage requirements, and common mistakes that destroy peptide potency.
MyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.